Literature DB >> 24651603

Comparing universal Lynch syndrome tumor-screening programs to evaluate associations between implementation strategies and patient follow-through.

Deborah Cragun1, Rita D DeBate2, Susan T Vadaparampil1, Julie Baldwin2, Heather Hampel3, Tuya Pal1.   

Abstract

PURPOSE: Universal tumor screening (UTS) for all colorectal cancer patients can improve the identification of Lynch syndrome, the most common cause of hereditary colorectal cancer. This multiple-case study explored how variability in UTS procedures influenced patient follow-through (PF) with germ-line testing after a screen-positive result.
METHODS: Data were obtained through Web-based surveys and telephone interviews with institutional informants. Institutions were categorized as Low-PF (≤10% underwent germ-line testing), Medium-PF (11-40%), or High-PF (>40%). To identify implementation procedures (i.e., conditions) unique to High-PF institutions, qualitative comparative analysis was performed.
RESULTS: Twenty-one informants from 15 institutions completed surveys and/or interviews. Conditions present among all five High-PF institutions included the following: (i) disclosure of screen-positive results to patients by genetic counselors; and (ii) genetic counselors either facilitate physician referrals to genetics professionals or eliminate the need for referrals. Although both of these High-PF conditions were present among two Medium-PF institutions, automatic reflex testing was lacking and difficulty contacting screen-positive patients was a barrier. The three remaining Medium-PF and five Low-PF institutions lacked the conditions found in High-PF institutions.
CONCLUSION: METHODS for streamlining UTS procedures, incorporating a high level of involvement of genetic counselors in tracking and communication of results and in reducing barriers to patient contact, are reviewed within a broader discussion on maximizing the effectiveness and public health impact of UTS.

Entities:  

Mesh:

Year:  2014        PMID: 24651603      PMCID: PMC4169758          DOI: 10.1038/gim.2014.31

Source DB:  PubMed          Journal:  Genet Med        ISSN: 1098-3600            Impact factor:   8.822


  29 in total

1.  How helpful is age at colorectal cancer onset in finding HNPCC?

Authors:  Patrick M Lynch
Journal:  Dis Colon Rectum       Date:  2011-05       Impact factor: 4.585

2.  Lynch syndrome screening in newly diagnosed colorectal cancer in general pathology practice: from the revised Bethesda guidelines to a universal approach.

Authors:  Jane Morrison; Mary Bronner; Brandie H Leach; Erinn Downs-Kelly; John R Goldblum; Xiuli Liu
Journal:  Scand J Gastroenterol       Date:  2011-08-31       Impact factor: 2.423

3.  Cancer risk in hereditary nonpolyposis colorectal cancer syndrome: later age of onset.

Authors:  Heather Hampel; Julie A Stephens; Eero Pukkala; Risto Sankila; Lauri A Aaltonen; Jukka-Pekka Mecklin; Albert de la Chapelle
Journal:  Gastroenterology       Date:  2005-08       Impact factor: 22.682

4.  Comparison between universal molecular screening for Lynch syndrome and revised Bethesda guidelines in a large population-based cohort of patients with colorectal cancer.

Authors:  Lucía Pérez-Carbonell; Clara Ruiz-Ponte; Carla Guarinos; Cristina Alenda; Artemio Payá; Alejandro Brea; Cecilia M Egoavil; Adela Castillejo; Victor M Barberá; Xavier Bessa; Rosa M Xicola; María Rodríguez-Soler; Cristina Sánchez-Fortún; Nuria Acame; Sergi Castellví-Bel; Virgínia Piñol; Francesc Balaguer; Luis Bujanda; María-Luisa De-Castro; Xavier Llor; Montserrat Andreu; Angel Carracedo; José-Luis Soto; Antoni Castells; Rodrigo Jover
Journal:  Gut       Date:  2011-08-25       Impact factor: 23.059

5.  Current priorities for public health practice in addressing the role of human genomics in improving population health.

Authors:  Muin J Khoury; Michael S Bowen; Wylie Burke; Ralph J Coates; Nicole F Dowling; James P Evans; Michele Reyes; Jeannette St Pierre
Journal:  Am J Prev Med       Date:  2011-04       Impact factor: 5.043

6.  Fostering implementation of health services research findings into practice: a consolidated framework for advancing implementation science.

Authors:  Laura J Damschroder; David C Aron; Rosalind E Keith; Susan R Kirsh; Jeffery A Alexander; Julie C Lowery
Journal:  Implement Sci       Date:  2009-08-07       Impact factor: 7.327

7.  The risk of extra-colonic, extra-endometrial cancer in the Lynch syndrome.

Authors:  Patrice Watson; Hans F A Vasen; Jukka-Pekka Mecklin; Inge Bernstein; Markku Aarnio; Heikki J Järvinen; Torben Myrhøj; Lone Sunde; Juul T Wijnen; Henry T Lynch
Journal:  Int J Cancer       Date:  2008-07-15       Impact factor: 7.396

8.  Impact of age cutoffs on a lynch syndrome screening program.

Authors:  James M Gudgeon; Thomas W Belnap; Janet L Williams; Marc S Williams
Journal:  J Oncol Pract       Date:  2012-11-13       Impact factor: 3.840

9.  Ten years after mutation testing for Lynch syndrome: cancer incidence and outcome in mutation-positive and mutation-negative family members.

Authors:  Heikki J Järvinen; Laura Renkonen-Sinisalo; Katja Aktán-Collán; Päivi Peltomäki; Lauri A Aaltonen; Jukka-Pekka Mecklin
Journal:  J Clin Oncol       Date:  2009-08-31       Impact factor: 44.544

10.  The cost-effectiveness of genetic testing strategies for Lynch syndrome among newly diagnosed patients with colorectal cancer.

Authors:  Mercy Mvundura; Scott D Grosse; Heather Hampel; Glenn E Palomaki
Journal:  Genet Med       Date:  2010-02       Impact factor: 8.822

View more
  31 in total

1.  Implementation of Universal Tumor Screening of Colorectal Cancer for Detection of Lynch Syndrome at a Hispanic-Rich County Hospital.

Authors:  Tyler W Snedden; Andrew McCracken; Anusha Vaidyanathan; Anna Taranova; Roberto Villarreal; Samina Qamar; Sukeshi Patel Arora
Journal:  JCO Oncol Pract       Date:  2020-05-22

2.  Differences in Microsatellite Instability Profiles between Endometrioid and Colorectal Cancers: A Potential Cause for False-Negative Results?

Authors:  Yang Wang; Chanjuan Shi; Rosana Eisenberg; Cindy L Vnencak-Jones
Journal:  J Mol Diagn       Date:  2016-11-01       Impact factor: 5.568

3.  Genetic counseling and cascade genetic testing in Lynch syndrome.

Authors:  Heather Hampel
Journal:  Fam Cancer       Date:  2016-07       Impact factor: 2.375

4.  Identification of a Variety of Mutations in Cancer Predisposition Genes in Patients With Suspected Lynch Syndrome.

Authors:  Matthew B Yurgelun; Brian Allen; Rajesh R Kaldate; Karla R Bowles; Thaddeus Judkins; Praveen Kaushik; Benjamin B Roa; Richard J Wenstrup; Anne-Renee Hartman; Sapna Syngal
Journal:  Gastroenterology       Date:  2015-05-14       Impact factor: 22.682

5.  Clinician-Stakeholders' Perspectives on Using Patient Portals to Return Lynch Syndrome Screening Results.

Authors:  Diane M Korngiebel; Kathleen M West; Wylie Burke
Journal:  J Genet Couns       Date:  2017-11-21       Impact factor: 2.537

Review 6.  Recent progress in Lynch syndrome and other familial colorectal cancer syndromes.

Authors:  Patrick M Boland; Matthew B Yurgelun; C Richard Boland
Journal:  CA Cancer J Clin       Date:  2018-02-27       Impact factor: 508.702

7.  Qualitative Comparative Analysis: A Hybrid Method for Identifying Factors Associated with Program Effectiveness.

Authors:  Deborah Cragun; Tuya Pal; Susan T Vadaparampil; Julie Baldwin; Heather Hampel; Rita D DeBate
Journal:  J Mix Methods Res       Date:  2015-02-25

Review 8.  Universal Screening of Colorectal Cancers for Lynch Syndrome: Challenges and Opportunities.

Authors:  Stephen M Vindigni; Andrew M Kaz
Journal:  Dig Dis Sci       Date:  2015-11-24       Impact factor: 3.199

9.  Universal Versus Targeted Screening for Lynch Syndrome: Comparing Ascertainment and Costs Based on Clinical Experience.

Authors:  Mujde Z Erten; Luca P Fernandez; Hank K Ng; Wendy C McKinnon; Brandie Heald; Christopher J Koliba; Marc S Greenblatt
Journal:  Dig Dis Sci       Date:  2016-07-06       Impact factor: 3.199

10.  Creation of a network to promote universal screening for Lynch syndrome: the LynchSyndrome Screening Network.

Authors:  Sarah Mange; Cecelia Bellcross; Deborah Cragun; Deb Duquette; Lisa Gorman; Heather Hampel; Kory Jasperson
Journal:  J Genet Couns       Date:  2014-09-16       Impact factor: 2.537

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.